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Kathryn B. Garber1,*LETM1 Identiﬁed as a Mitochondrial Calcium
Transporter
I would expect that in response to the question ‘‘What are
mitochondria?’’ most of us would blurt back, ‘‘The power-
house of the cell.’’ But beyond this obvious function, mito-
chondria are also very important as intracellular calcium
repositories that participate in calcium signaling. The
mitochondria can use this link to regulate the activity
of their energy-generating enzymes. Mitochondria have
been known for a while to possess tightly regulated
calcium transporters, but these proteins have been charac-
terized on a functional level only; their identities have
been unknown. That is, until a genome-wide RNAi screen
allowed Jiang et al. to identify Letm1 as a mitochondrial
Ca2þ/Hþ antiporter. This transporter brings Ca2þ into the
mitochondria in exchange for Hþ, and experiments in
liposomes indicate that this is a one-to-one exchange
and that this process is electrogenic. Besides going beyond
our simple deﬁnition of the function of mitochondria,
the identiﬁcation of Letm1 as a mitochondrial calcium
transporter is important for an additional reason: the
human homolog, LETM1, is deleted in nearly all patients
with Wolf-Hirschhorn syndrome. The pathogenesis of this
subtelomeric deletion syndrome, which includes mental
retardation, epilepsy, growth delay, and a characteristic
facial appearance, has been unclear. Perhaps the identity
of LETM1 will lead to increased understanding of the
etiology of this disorder.
Jiang et al. (2009). Science 326, 144–147. 10.1126/
science.1175145.
Should Everybody Have Access to GWAS Data?
Last year, Homer et al. published in PLoS Genetics a paper
(PLoS Genet. 4, e1000167) that led some researchers and
policy makers to question the wisdom of making data
from genome-wide association studies (GWASs) publicly
available. The Homer et al. paper suggested that if you
had a person’s individual genotype data, you could deter-
mine whether their DNA was present in a mixed sample
from which only marker allele frequencies were known.
In terms of a GWAS, the fear is that somebody could
take a person’s genotype information and then ﬁgure
out whether they were in the case or the control sample
in a publicly available GWAS data set. Inferences about
the person’s disease status could then be made. As the
GWAS came into vogue, the National Institutes of HealthThe Americahad a two-tiered access policy for GWAS data. In
level 1, summary information and aggregate genotype
data, including marker allele frequencies by case-control
status, were made publicly available. In level 2, indi-
vidual-level data on study participants weremade available
only to qualiﬁed researchers who submitted an application
for access. In response to the Homer et al. paper, modiﬁca-
tions to this policy were rapidly implemented, in which
aggregate genotype data were removed from public access.
In a recent issue of PLoS Genetics, three articles explore the
ramiﬁcations of the work by Homer et al. In the ﬁrst article,
several researchers contribute their views on how policy
changes and research should proceed from here. Their
suggestions range from setting an internationally agreed
upon code of conduct for scientists working with genome
data to granting wide access to the genomic data with
the understanding by research participants that full disclo-
sure of their genetic information will be made. A research
article by Visscher and Hill and another by Braun et al.
put Homer’s metric to the test to determine its power
and limitations.
P3G Consortium et al. (2009). PLoS Genet 5, e1000665.
10.1371/journal.pgen.1000665.
Visscher and Hill (2009). PLoS Genet 5, e1000628.
10.1371/journal.pgen.1000628.
Braun et al. (2009). PLoS Genet 5, e1000668. 10.1371/
journal.pgen.1000668.
Comparing Results from Two Direct-to-Consumer
Personal Genome Scans
Whether we argue about how the currently marketed
direct-to-consumer (DTC) genome scans are regulated or
about whether they should even be able to provide this
service, the fact is that several such scans are available
and have already been used by thousands of people. There
are many decisions that go into turning a saliva sample
into a set of risk calculations, which leaves me to wonder
how well the risk calculations agree among DTC compa-
nies. Now, I need not wonder any longer—in the October
8 issue of Nature, which has a focus on human genetics,
Pauline Ng et al. sent samples from the same set of ﬁve
individuals to both 23andme and Navigenics and com-
pared the risk analyses performed by both companies.
Because both companies pull data from the publicly avail-
able results of genome-wide association studies, it is not
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diseases. For other diseases, though, the two companies
don’t agree even in the direction of the relative risk for
all individuals. This is in large part due to differences in
the criteria for the selection of genetics markers included
in the risk calculations, but it does highlight how much
we have to learn about genetic contributions to common
diseases, and it leaves me wary as to how much the
average consumer appreciates about these risk predictions.
Ng et al. propose a set of recommendations that they think
personal genomics companies would be wise to follow,
including the idea that the companies should make clear
to consumers the fraction of disease risk that the geno-
typed markers can explain, which for many disorders is
very little. The authors also argue for research monitoring
how personal genome scans alter consumer behavior and
how well these approaches actually predict disease risk in
prospective studies.
Ng. et al. (2009). Nature 461, 724–726. 10.1038/461724a.
The Location and Role of Human CNVs
Genome-wide association studies (GWASs) were never
designed to ﬁnd all of the genetic variation that contrib-
utes to complex diseases. Nevertheless, the fact that the
results coming from these studies account for only a small
fraction of trait variation in most cases is rather disap-
pointing. In a recent issue of Nature, Manolio et al. explore
some of the potential sources of this ‘‘missing heritability,’’
which range from undetected rare variants to inﬂated heri-
tability estimates. Copy number variation (CNV) could be
another underappreciated contributor to trait variation,
and Manolio et al. call for further exploration of the role
of CNV in complex disease. A resource that will greatly
aid this exploration is the most complete map of human
copy-number variants (CNVs) that has been published to
date, which was created by Conrad et al. Their goal was
to create a map of all CNVs of 1 kb or larger, and they esti-
mate that they ultimately found 80%–90% of those with a
minor allele frequency greater than 5%. However, an anal-
ysis by Conrad et al. indicates that most of their CNVs are
well-tagged by SNPs, and so they suggest that existing
GWASs have already indirectly looked at associations
with these CNVs. On the basis of this ﬁnding, Conrad542 The American Journal of Human Genetics 85, 541–543, Novemet al. don’t view common CNVs as a main contributor to
the missing heritability problem.
Conrad et al. (2009). Nature. Published online October 7,
2009. 10.1038/nature08516.
Manolio et al. (2009). Nature 461, 747–753. 10.1038/
nature08494.
Role for siRNAs in Chromosome Segregation
The kinetochore is a complex assembly of proteins to
which the spindle ﬁbers attach and subsequently pull the
chromosomes to opposite poles during anaphase. During
the cell cycle, the chromosomes should align at the meta-
phase plate and the kinetochores should be oriented to the
opposing spindle poles. Claycomb et al. identify a small
RNA-based system that is crucial for this process and for
proper chromosome segregation in C. elegans. They ﬁnd
a class of small RNAs, called 22G-RNAs, that are antisense
to more than 4000 protein-coding genes in the C. elegans
genome and are associated with the Argonaute protein
CSR-1. Rather than regulating gene expression, the 22G-
RNAs appear to target CSR-1 to genomic loci that are
distributed fairly uniformly along the chromosomes.
These euchromatic domains support the proper alignment
of the kinetochores through a mechanism that is as yet
undeﬁned. Without CSR-1, chromosomes don’t align
properly at the metaphase plate and the kinetochores
don’t orient to opposite poles. van Wolfswinkel et al. iden-
tiﬁed another crucial component of this system. They
found that CDE-1 uridylates the 30 end of the CSR-1-asso-
ciated siRNAs, thereby destabilizing them. In the absence
of CDE-1, these siRNAs are overexpressed, and this loss
of function is also associated with defects in chromosome
segregation. Granted, unlike mammals, C. elegans centro-
meres are spread along the length of the chromosome
rather than localized to one distinct area, but the conserva-
tion of CDE-1 throughout the animal kingdom suggests
this siRNA-based system for regulation of chromosome
segregation may be more widespread.
Claycomb et al. (2009). Cell 139, 123–134. 10.1016/
j.cell.2009.09.014.
vanWolfswinkel et al. (2009). Cell 139, 135–148. 10.1016/
j.cell.2009.09.012.This Month in Our Sister Journals
Low Uptake of Genetic Services for Lynch Syndrome
Assessment
‘‘If you build it, they will come’’ might have worked in
baseball, but what about genetic testing? If you develop
a genetic testing protocol and identify patients who
might beneﬁt from this analysis, will patients accept the
referral? This probably wasn’t the question that South
et al. hoped they were going to address when they explored
an approach to identifying people with colorectal cancer
who might be at risk of Lynch syndrome. However, it
was one of the more striking results of their study. Lynch
syndrome predisposes affected individuals to visceral
cancers, particularly colorectal cancer (CRC), and is caused
by a defect in DNA mismatch repair (MMR). These defectsber 13, 2009
can be detected through the absence of MMR proteins
in a tumor sample and/or the instability of microsatellite
sequences. Because only a minority of CRCs are due to
Lynch syndrome, clinical criteria have been used for
selecting which tumors are appropriate for the evaluation
of MMR defects. South et al. felt that this approach
could lead to underdiagnosis of Lynch syndrome, so they
decided to explore the feasibility of evaluating all CRCs
for the expression of MMR proteins as a way of detecting
Lynch syndrome. Immunohistochemical staining of four
MMR proteins was performed on all 270 CRC cases that
were diagnosed over a two-year period at the Ohio State
University Medical Center. Of the 57 cases in which the
tumor lacked staining for one or more MMR proteins,
further evaluation indicated that 34 of these might
beneﬁt from a genetics consultation, and the affected indi-
viduals were contacted. Surprisingly, only nine of these
individuals kept their appointments with the genetics
clinic to discuss the possibility of further testing for Lynch
syndrome, and two of these individuals were ultimately
diagnosed with Lynch syndrome, which is a minority of
the expected number of cases in this sample. From a scien-
tist’s point of view, the identiﬁcation of Lynch syndrome is
important in that it can affect the clinical management of
CRC and also has implications for cancer risk in the family
members of affected individuals. The low uptake of genetic
consultation in this sample indicates that we need to look
at how we deliver, and how patients receive, this informa-
tion to identify the barriers to uptake of genetic evaluation.
South et al. (2009). Genet. Med. 11, 812–817. 10.1097/
GIM.0b013e3181b99b75.
Promiscuous Proteins
The formation of amyloid ﬁbrils is associated with several
disease states. A classic example is b-amyloid in AlzheimerThe Americandisease, but various other proteins have the capacity to
form these aggregates under certain conditions. Although
we don’t fully understand how this happens, we do
know that once the aggregation of the amyloid protein
starts, or is seeded, the process really takes off. Not only
can one amyloid protein seed its own amyloid aggrega-
tion, there can be cross-seeding of other amyloid proteins
into ﬁbrils. Ross et al. used yeast prions, which are infec-
tious amyloid forms of normal yeast proteins, as a model
system to study cross-seeding of amyloid formation.
They looked at the Ure2p transition to [URE3] prions and
found that cross-seeding might be more widespread than
previously suspected. If they took a fragment of Ure2p
and scrambled up the pieces so that they had a totally
different amino acid order, this scrambled sequence
could still prime [URE3] formation in a mechanism that
involved direct interaction between the scrambled protein
sequence and the wild-type protein. Because the amino
acid composition, and not the primary protein sequence,
was important for amyloid seeding, the authors used
a simple algorithm to search the yeast proteome for protein
fragments with a composition similar to that of the Ure2p
prion domain. Of the ﬁve protein fragments that were
most similar to the Ure2p prion domain, four of them
could cross-seed [URE3] formation, hinting that there is
much more promiscuity in seeding amyloid formation
than we were aware of. Strikingly, the efﬁciency of the
cross-seeding, which was previously thought to be low,
was actually almost as high as that of the homologous
Ure2p prion domain. We don’t yet know whether the
same type of cross-seeding occurs in humans, but if it
does, this could help further our understanding of the
process by which amyloid aggregates initiate.
Ross et al. (2009). Genetics. Published online September 14,
2009. 10.1534/genetics.109.109322.Journal of Human Genetics 85, 541–543, November 13, 2009 543
